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:   vascular endothelial growth factor
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:   vascular endothelial growth factor receptor

1. INTRODUCTION {#jcp28346-sec-0010}
===============

One of the hallmarks in the development of solid tumors is tumor angiogenesis, the process of new blood vessel growth in tumor tissues from the pre‐existing vasculatures (Folkman, [1971](#jcp28346-bib-0048){ref-type="ref"}; Hida, Maishi, Annan, & Hida, [2018](#jcp28346-bib-0016){ref-type="ref"}). The angiogenic activity of endothelial cells arises in response to various growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor released from the neighboring tumor cells (Carmeliet & Jain, [2011](#jcp28346-bib-0009){ref-type="ref"}). By receiving a variety of stimuli including VEGF, the endothelial cells lining the inner layer of blood vessels drastically change their characteristics (e.g., growth, motility, adhesion, cell--cell contact), leading to angiogenesis (Potente, Gerhardt, & Carmeliet, [2011](#jcp28346-bib-0042){ref-type="ref"}). Tumor angiogenesis is critical for not only the tumor growth beyond a few millimeters in size by the supply of nutrients and oxygen but also the tumor metastasis by providing the passage to other tissues (Maishi & Hida, [2017](#jcp28346-bib-0033){ref-type="ref"}). Thus, the inhibition of angiogenesis can suppress tumor growth and metastasis (Folkman, [1971](#jcp28346-bib-0048){ref-type="ref"}). Among the complicated molecular mechanisms of angiogenesis, VEGF‐dependent proliferative signals through the vascular endothelial growth factor receptors (VEGFRs) have been attractive targets for developing the anticancer drugs (Ferrara & Adamis, [2016](#jcp28346-bib-0015){ref-type="ref"}). To date, antiangiogenic drugs such as bevacizumab (humanized monoclonal antibody for VEGF‐A) and sunitinib (tyrosine kinase inhibitor of VEGFRs) have been successfully developed and used to cure cancers (e.g., colorectal cancer, lung cancer, and renal cell carcinoma; Clarke & Hurwitz, [2013](#jcp28346-bib-0010){ref-type="ref"}).

Among a variety of solid tumors, colorectal cancers exhibit high tumor angiogenic activities (Mathonnet et al., [2014](#jcp28346-bib-0034){ref-type="ref"}). In fact, bevacizumab is administrated as first or second line treatment of colorectal cancer, which is highly effective (De Falco, [2014](#jcp28346-bib-0013){ref-type="ref"}). In the randomized phase III study of the metastatic colorectal cancer therapy combination with oxaliplatin, the progression‐free survival and overall survival were 9.4 months and 21.3 months in the bevacizumab‐treated group, and 8.0 months and 19.9 months in the placebo group (Saltz et al., [2008](#jcp28346-bib-0043){ref-type="ref"}). Despite the good efficacy of bevacizumab in treating colorectal cancer, the development of drug resistance after long‐term administration often poses a major challenge (Bergers & Hanahan, [2008](#jcp28346-bib-0007){ref-type="ref"}; Lupo et al., [2016](#jcp28346-bib-0030){ref-type="ref"}). In addition, the anti‐VEGF antibodies and VEGFR inhibitors occasionally cause hypertension and gastrointestinal perforation as side effects (de Jesus‐Gonzalez, Robinson, Moslehi, & Humphreys, [2012](#jcp28346-bib-0021){ref-type="ref"}; Sliesoraitis & Tawfik, [2011](#jcp28346-bib-0049){ref-type="ref"}). To overcome these issues, the development of novel antiangiogenic drugs targeting molecular machinery instead of the VEGF/VEGFR axis is required.

During the complicated multistep angiogenesis, endothelial cells receive stimulations through transmembrane proteins (e.g., VEGFRs, Notch ligands, Notch receptors, vascular endothelial‐cadherin, integrins) on their cell surface, leading to proper angiogenic responses (Horowitz & Seerapu, [2012](#jcp28346-bib-0018){ref-type="ref"}; Kandachar & Roegiers, [2012](#jcp28346-bib-0024){ref-type="ref"}). The localization of these membrane proteins in the plasma membrane (PM) is balanced by the rate of their endocytosis from the PM to the endosomes and their recycling from the endosomes to the PM (Mellman & Yarden, [2013](#jcp28346-bib-0035){ref-type="ref"}). The manipulation of membrane trafficking of these angiogenic cargos in endothelial cells could inhibit angiogenesis (Maes, Olmeda, Soengas, & Agostinis, [2016](#jcp28346-bib-0032){ref-type="ref"}). Thus, we aimed to identify novel angiogenic molecules involved in the intracellular membrane trafficking, which could be targeted for the development of new antiangiogenic drugs.

In this study, by utilizing the siRNA library for the sorting nexin (SNX) family, which regulates a variety of intracellular membrane trafficking processes, we found that sorting nexin 9 (SNX9) was essential for the tube formation that mimics in vivo angiogenesis of human umbilical vein endothelial cells (HUVECs). SNX9 was essential for determining the surface levels of integrin β1 as well, suggesting a possible molecular mechanism by which SNX9 regulates tube formation. In patients with human colorectal cancer, SNX9 was highly expressed in the tumor endothelial cells. Our results suggest that SNX9 is a novel angiogenic factor that regulates the recycling of integrin β1.

2. MATERIALS AND METHODS {#jcp28346-sec-0020}
========================

2.1. Antibodies {#jcp28346-sec-0030}
---------------

The following antibodies were purchased from the manufacturers as indicated: rabbit anti‐SNX9 antibody (HPA031410; dilution 1:1000 for western blot analysis; dilution 1:750 for immunohistochemistry; Sigma, Tokyo, Japan), rabbit anti‐SNX5 antibody (ab180520; dilution 1:1000; Abcam, Tokyo, Japan), rabbit anti‐CD31 antibody (ab28364; dilution 1:100 for immunohistochemistry; Abcam), goat anti‐integrin β1 antibody (N‐20, dilution 1:1000 for western blot analysis; Santa Cruz, Dallas, TX), mouse anti‐integrin β1 antibody (P5D2, dilution 1:1000; R&D systems, Minneapolis, MN), mouse anti‐integrin β1 antibody (TS2/16, dilution 1:500 for western blot analysis and immunofluorescence; Biolegend, San Diego, CA), Alexa488‐conjugated mouse anti‐integrin β1 antibody (TS2/16, dilution 1:200; BioLegend), mouse anti‐GAPDH antibody (5A12, dilution 1:6000; Wako, Tokyo, Japan), mouse anti‐Myc antibody (9E10; dilution 1:1000; Santa Cruz), HRP‐conjugated anti‐mouse‐IgG antibody (W4021; dilution 1:2000; Promega, Tokyo, Japan), horse radish peroxidase (HRP)‐conjugated anti‐rabbit‐IgG antibody (W4011; dilution 1:2000; Promega, Tokyo, Japan), HRP‐conjugated anti‐goat‐IgG antibody (V805A; dilution 1:2000; Promega), goat Alexa488‐conjugated anti‐mouse‐IgG antibody (A11001; dilution 1:2000; Molecular Probes, Eugene, OR), and goat Alexa568‐conjugated anti‐mouse‐IgG antibody (A11004; dilution 1:2000; Molecular Probes).

2.2. Plasmids {#jcp28346-sec-0040}
-------------

Myc‐SNX9 was amplified from a vector containing the human SNX9 complementary DNA (cDNA; a kind gift from Ms. Yuki Tanaka, Ehime University) using the following pairs of primers: 5′‐ATGGAACAAAAACTCATCTCAGAAGAGGATCTGATGGCCACCAAGGCTCGGGT‐3′ (Myc‐SNX9 sense primer) and 5′‐CTACATCACTGGAAAGCGGC‐3′ (SNX9 antisense primer). The PCR product was introduced into the blunt end of the CSII‐CMV‐MCS‐IRES2‐Bsd vector. GFP‐Rab5, GFP‐Rab7, GFP‐Rab11, or LAMP1‐GFP in the CSII‐CMV‐MCS‐IRES2‐Bsd vector (Maekawa et al., [2017](#jcp28346-bib-0031){ref-type="ref"}) were used for the co‐localization experiments. Full length and the LC‐PX domain of SNX9 were amplified from the vector containing the human SNX9 cDNA using the following pairs of primers: 5′‐ATGGCCACCAAGGCTCGGGT‐3′ (SNX9 sense primer), 5′‐CTACATCACTGGAAAGCGGC‐3′ (SNX9 antisense primer), 5′‐GACTACGTTGAAATTTTACC‐3′ (LC‐PX sense primer), and 5′‐CTATCGGAAATTTAGGAACT‐3′ (LC‐PX antisense primer). The PCR products were introduced into the blunt end of the pEU‐N‐bls vector. Bls‐SNX9 (ΔLC) was generated with the following pairs of primers: 5′‐ACTTTTGACTGTGTGGTAGCAGATC‐3′ (sense primer) and 5′‐TGTGGGAACCAGCCCTCGTTCTCCT‐3′ (antisense primer).

2.3. Cell culture {#jcp28346-sec-0050}
-----------------

HUVECs were purchased from Cell Systems (Kirkland, WA) and Lonza (Tokyo, Japan). HUVECs were maintained at 37°C with 5% CO~2~ in EBM‐2 (Lonza) according to the manufacturer\'s instructions. HUVECs at passage 2--4 were used for experiments. HEK293T cells were maintained at 37°C with 5% CO~2~ in Dulbecco\'s modified Eagle\'s medium (Wako) supplemented with 10% fetal bovine serum (FBS), 20 units/ml penicillin, and 100 µg/ml streptomycin.

2.4. Transfection {#jcp28346-sec-0060}
-----------------

Transfections of siRNAs (25 nM) into HUVECs were performed using RNAimax (Invitrogen, Tokyo, Japan) according to the manufacturer\'s instructions. Subsequent experiments were performed at 72 hr posttransfection. Transfection of plasmids into HEK293T cells was performed using GeneJuice (Millipore, Burlington, MA) according to the manufacturer\'s instructions.

2.5. Small interfering RNAs {#jcp28346-sec-0070}
---------------------------

The following validated siRNA duplex oligomers were purchased and used for the knockdown experiments: GUUGCAAGCUGAGAUGAAU (siSNX9 \#1; Sigma), CAUCGAAUAUCAGCUAACA (siSNX9 \#2; Sigma), GAAUGUAAUCACGAGUAUA (siSNX9 \#3; Sigma), GGGACUUUGUAGAGAAUUU (siSNX9 \#4 targeting the 3′‐UTR of the human SNX9 messenger RNA (mRNA); Sigma; Bendris, Williams, et al., [2016](#jcp28346-bib-0006){ref-type="ref"}). The list of SNX genes and siRNA duplex oligomers (Sigma) used for the siRNA screening are shown in Table [1](#jcp28346-tbl-0001){ref-type="table"}. Control siRNA was purchased from Sigma (SIC‐001).

###### 

List of human SNX genes and siRNA duplex oligomers used for siRNA screening

  SNX gene   Sequence of siRNA duplex targeting the SNX genes
  ---------- --------------------------------------------------
  SNX1       GACAUUGAGUGGUGCUGGU
  SNX2       GGAAGAUGCUCAAAUUACU
  SNX3       GACUAUUAAUGAUUGAUAA
  SNX4       CUCACUAUGGCGGCGAUAU
  SNX5       CAGUAAAGAUCGCAACUUU
  SNX6       CUGCUAAGGAUCUCCUGUA
  SNX7       GAAAGAAUAUGGCCCAAUU
  SNX8       GGAUGUGCAGAACAAGUUA
  SNX9       GUUGCAAGCUGAGAUGAAU
  SNX10      CAAUUCACAAGUUUGCCUU
  SNX11      CUGAGUUUCUGCAGGUCAU
  SNX12      GACAAACCUACCUAUCUUC
  SNX13      GAGUUUCGGCUCAACUUGA
  SNX14      CACAAUUUCUUGAUAAGAU
  SNX15      CCCAGAGGAUGUCAAAGAG
  SNX16      GUGAACAGAUCCUAAAGGU
  SNX17      GCUUUAUGCUCAGACGGUA
  SNX18      GACUUCAUCUCUAAGCGCA
  SNX19      CUCAAUAACCUGUUGAGUA
  SNX20      CUGAGGAGAUGAUCUGUGA
  SNX21      CAGAUUGCCAGCCAGCCCA
  SNX22      CUGAUCAGUCCAGAGGCCU
  SNX23      GGCUUAAUACCUCGGAUCU
  SNX24      GUGAUAGUACAUUCUGAAA
  SNX25      GCAACUAAGGUAUCAAAUU
  SNX26      CACAUUCAGCUCCUGCUGU
  SNX27      CUCUACAUUCAGAAUUAUA
  SNX28      GCGCGUGUUGGAAACGUCA
  SNX29      GAGAGAACGAGGUGCUCAA
  SNX30      GACUAGAGAUCUCUUCGUU
  SNX31      GUAAAGCUAGCUGCUGAGA
  SNX32      CAGACAUGCUGAGGUACUA
  SNX33      CAUCAGAGCUGGUGCGUAA

*Note*. siRNA: small interfering RNA; SNX: sorting nexin.

John Wiley & Sons, Ltd.

2.6. Lentiviral expression {#jcp28346-sec-0080}
--------------------------

Lentiviruses carrying Myc‐SNX9, GFP‐Rab5, GFP‐Rab7, GFP‐Rab11, or LAMP1‐GFP were produced by the transfection of those cDNA cloned in the CSII‐CMV‐MCS‐IRES2‐Bsd vector with two packaging vectors (the pCAG‐HIVgp vector and pCMV‐VSVG‐RSV‐Rev vector) into HEK293T cells. At 48 hr posttransfection, the lentiviruses in the medium were collected. At 24 hr posttransfection of siRNA into HUVECs, the collected lentiviruses were added into the medium of the HUVECs. The expression of Myc‐SNX9 and GFP‐tagged organelle markers in HUVECs was detected at 48 hr post‐lentiviral infection. The CSII‐CMV‐MCS‐IRES2‐Bsd, pCAG‐HIVgp, and pCMV‐VSVG‐RSV‐Rev vectors were kind gifts from Dr. Hiroyuki Miyoshi (RIKEN, Tokyo, Japan).

2.7. Western blot analysis {#jcp28346-sec-0090}
--------------------------

Proteins were subjected to sodium dodecyl sulfate (SDS) poly‐acrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (BioRad, Hercules, CA). After blocking of these membranes in 5% skim milk in 0.05%‐Tween‐20/TBS buffer, the membranes were incubated with the primary antibodies, followed by the secondary antibodies conjugated to peroxidase in 5% skim milk in 0.05%‐Tween‐20/TBS buffer. The proteins were visualized by enhanced chemiluminescence using a LAS‐4000 (GE Healthcare, Tokyo, Japan). To detect integrin β1 using TS2/16, the cell lysates were collected under nonreducing conditions. Except for the experiments using TS2/16, all the cell lysates were collected under reducing conditions.

2.8. Immunofluorescence staining {#jcp28346-sec-0100}
--------------------------------

Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 30 min at room temperature and permeabilized with 0.1% Triton X‐100 in PBS for 15 min at room temperature. After blocking with 3% bovine serum albumin (BSA) in PBS for 1 hr at room temperature, the cells were incubated with primary antibodies at 4°C overnight and then with secondary antibodies conjugated to fluorophores at room temperature for 1 hr. To stain the nuclei, the fixed cells were treated with Hoechst33342 (dilution 1:2000; Molecular Probes) at room temperature for 1 hr.

2.9. Phalloidin staining {#jcp28346-sec-0110}
------------------------

Cells were fixed with 4% PFA in PBS for 30 min at room temperature and permeabilized with 0.1% Triton X‐100 in PBS for 15 min at room temperature. After blocking with 3% BSA in PBS for 30 min at room temperature, the cells were incubated with rhodamine‐conjugated phalloidin (dilution 1:1000; Molecular Probes) for 1 hr at room temperature.

2.10. Biotinylation assay {#jcp28346-sec-0120}
-------------------------

The biotinylation assays were performed as described previously (Maekawa et al., [2017](#jcp28346-bib-0031){ref-type="ref"}). Briefly, the HUVECs were washed with ice‐cold PBS two times followed by incubation with biotin solution (0.1 mg/ml; sulfo‐NHS‐biotin; Thermo Fisher Scientific; (Tokyo, Japan) in 0.1 M Hepes; 0.15 M NaCl; pH 8.0) for 15 min at 4°C. After quenching with ice‐cold serum‐containing EBM‐2 medium, the cells were subjected to immunoprecipitation. The cells were lysed in 0.5 ml of IP buffer (25 mM Tris‐HCl; pH 7.4; 150 mM NaCl; 1% NP‐40; 1 mM EDTA; 5% glycerol) containing the complete protease inhibitors (Roche). After incubation of the cell lysates on ice for 10 min, the cell lysates were centrifuged at 10,000*g* for 10 min at 4°C. The resultant supernatants were incubated with streptavidin magnetic beads (Dynabeads M‐280; Invitrogen) for 1 hr at 4°C. The beads were washed with IP buffer three times followed by the collection of proteins with SDS buffer without 2‐mercaptoethanol. The total and biotinylated integrin β1 were detected by western blot analysis using the TS2/16 antibody.

2.11. Integrin β1 uptake and recycling assays {#jcp28346-sec-0130}
---------------------------------------------

The internalization and recycling assays of integrin β1 were performed as described previously (Arjonen, Alanko, Veltel, & Ivaska, [2012](#jcp28346-bib-0001){ref-type="ref"}). Briefly, integrin β1 on the cell surface of HUVECs was labeled with Alexa488‐conjugated TS2/16 antibody in the growth‐EBM‐2 medium containing 30 mM Hepes (pH 7.6) on ice for 1 hr. Cells were then washed with ice‐cold PBS and the medium was replaced with fresh growth medium containing 30 mM Hepes (pH 7.6). For the internalization assay, the cells were incubated at 37°C with 5% CO~2~ for the indicated time‐point. After the internalization, the cells were put on the ice and the fluorescence on the cell surface was quenched by adding anti‐Alexa488 antibody and incubating on ice for 1 hr. To monitor the recycling of integrin β1, labeled integrin β1 on the cell surface was allowed to internalize for 1 hr at 37°C with 5% CO~2~ followed by quenching of the surface integrin β1. Cells were incubated again at 37°C with 5% CO~2~ for the indicated time‐point. After incubation, the surface fluorescence signal of integrin β1 was quenched again. For imaging, the cells were fixed with 4% PFA in PBS for 30 min at room temperature. The fluorescence intensity of Alexa488 excluding the background fluorescence intensity was quantified with ImageJ (NIH). The fluorescence intensities were normalized against the total surface staining (at 0 min before quenching, for the uptake assay) or total internalized staining (for the recycling assay).

2.12. Transferrin uptake and recycling assays {#jcp28346-sec-0140}
---------------------------------------------

The internalization and recycling assays of transferrin were performed as described previously (Lee et al., [2015](#jcp28346-bib-0029){ref-type="ref"}). For the uptake assay, HUVECs were serum‐starved in EBM‐2 for 30 min at 37°C. The cells were then incubated with 50 μg/ml of Alexa488‐transferrin (Molecular Probes) in 0.15% serum‐containing EBM‐2 for 5 or 10 min at 37°C. The cells were then chilled on ice and incubated in acid‐wash buffer (20 mM sodium‐acetate buffer; 1 mM CaCl~2~; 150 mM NaCl; pH 4.8) on ice for 5 min to remove Alexa488‐transferrin in the PM. For the recycling assay, HUVECs were incubated in 0.15% serum‐containing EBM‐2 for 30 min at 37°C followed by incubation in 0.15% serum‐containing EBM‐2 containing 50 μg/ml Alexa488‐transferrin for 1 hr at 37°C. After washing with ice‐cold PBS, the cells were incubated in the acid‐wash buffer on ice for 5 min to remove the surface‐bound Alexa488‐transferrin. Cells were washed with ice‐cold PBS and chased in growth‐EBM‐2 medium containing 400 μg/ml unlabeled human holo‐transferrin (Thermo Fisher Scientific) at 37°C with 5% CO~2~. For imaging, the cells were fixed with 4% PFA in PBS at room temperature for 30 min. The fluorescence intensity of Alexa488 excluding the background fluorescence intensity was quantified with ImageJ (NIH).

2.13. Spreading and network formation on the Matrigel {#jcp28346-sec-0150}
-----------------------------------------------------

HUVECs were collected by treatment with trypsin for 1 min followed by seeding on the Matrigel basement membrane (BD Matrigel™ Basement Membrane Matrix Growth Factor Reduced; BD Biosciences, Tokyo, Japan). The cells were then incubated in the growth‐EBM‐2 medium for 1 hr or 12 hr at 37°C with 5% CO~2~. The cells were fixed and F‐actin was stained with rhodamine‐conjugated phalloidin. The cell size and network length were measured with ImageJ (NIH, Bethesda, MD).

2.14. Tube formation assay {#jcp28346-sec-0160}
--------------------------

Collagen I gel was reconstituted by mixing Nitta gelatin Type I‐A collagen gel (Nitta Gelatin; 180712), 10× 199 medium (Nitta Gelatin; 180517), reconstitution buffer (Nitta Gelatin; 181126, Osaka, Japan). HUVECs (0.5 × 10^5^ cells/well of 12 well plates) seeded on the reconstituted collagen I gel were subjected to siRNA transfection. At 6 hr post‐siRNA transfection, the cells were packed with collagen I again, followed by the addition of 50 ng/mL VEGF‐A (R&D Systems) in 0.15% serum and heparin‐containing EBM‐2 medium. Tube formation of HUVECs was observed at 66 hr after the addition of VEGF‐A. The cells were fixed and F‐actin was stained with rhodamine‐conjugated phalloidin. The tube length was measured with ImageJ (NIH).

2.15. Cell proliferation assay {#jcp28346-sec-0170}
------------------------------

The cell proliferation assay was performed as described previously (Murakami et al., [2019](#jcp28346-bib-0036){ref-type="ref"}) with slight modifications. A total of 0.5 × 10^5^ HUVEC were seeded into a six‐well plate in triplicate. Cells were treated with siRNA on the next day. After 48 hr, 0.5 × 10^5^ cells were replated into a 12‐well plate in triplicate. On the next day, cells were then treated with the same siRNA again, and cultured in growth‐EBM‐2 medium with or without VEGF‐A (50 ng/ml). The cells were counted at each time points after siRNA transfection.

2.16. Cell migration assay {#jcp28346-sec-0180}
--------------------------

A total of 0.5 × 10^5^ HUVEC were seeded into collagen I‐coated 35 mm dishes (IWAKI, Shizuoka, Japan). Cells were treated with siRNA on the next day. After 72 hr, the cell culture was scratched with a 1000 μl pipette tip, followed by incubation with growth‐EBM‐2 medium for 15 hr. Images were obtained using a microscope (Olympus, Tokyo, Japan), and analyzed with Fiji software (NIH).

2.17. Confocal microscopy {#jcp28346-sec-0190}
-------------------------

Confocal microscopy was performed using the A1R laser confocal microscope (Nikon, Tokyo, Japan) with a 60 × 1.27 Plan‐Apochromat water immersion lens or a 10 × 0.45 Plan‐Apochromat lens. Images were analyzed with ImageJ or Fiji software (NIH).

2.18. Protein synthesis using wheat germ cell‐free system {#jcp28346-sec-0200}
---------------------------------------------------------

The transcription and translation for the production of biotinylated recombinant proteins were performed using WEPRO7240 Expression Kit (CellFree Science, Matsuyama, Japan), according to the manufacturer\'s instructions with slight modifications. The mRNA templates were generated by incubating for 6 hr at 37°C in a mixture containing 2 μl of 5× transcription buffer, 1 μl of 25 mM NTP mix, 0.1 μl of 80 U/μl RNase inhibitor, 0.1 μl of 80 U/μl SP6 RNA polymerase, 1 μg pEU vectors (Bls‐SNX9, WT; Bls‐SNX9, ΔLC; Bls‐LC‐PX) and RNase‐free water (up to 10 μl). For cell‐free translation of mRNA templates, the mixtures for lower and upper layer were prepared as follows: lower layer \[6.25 μl of WEPRO7240, 0.25 μl of 20 μg/μl creatine kinase (Roche, Basel, Switzerland), 4.68 μl of 4 ×  SUB‐AMIX, 10 μl of mRNA templates, 1 μl of recombinant Bir‐A (a kind gift from Dr. Hiroyuki Takeda, Ehime University), 1 μl of 12.5 μM D‐biotin (Sigma), 1.82 μl of RNase‐free water (total 25 μl)\]; upper layer \[31.25 μl of 4 ×  SUB‐AMIX, 5 μl of 12.5 μM D‐biotin, 88.75 μl of RNase‐free water (total 125 μl). The upper layer mixture was added to a well of 96‐well flat bottom plate followed by the addition of the lower layer mixture into the bottom, carefully. The reaction mixtures were incubated for 24 hr at 16°C to produce recombinant proteins. The reaction mixtures (total 150 μl/well) were centrifuged at 10,000*g* for 10 min at 4°C. The resultant supernatants were subjected to western blot analysis to detect the production of recombinant proteins. The biotinylated proteins were detected using the VECTASTAIN ABC kit (Funakoshi, Tokyo, Japan).

2.19. Immunohistochemistry and H&E staining {#jcp28346-sec-0210}
-------------------------------------------

Immunohistochemical staining of colorectal cancer tissues was carried out as described previously (Kiyoi, [2018](#jcp28346-bib-0026){ref-type="ref"}) with slight modifications. Briefly, the formaldehyde‐fixed paraffin‐embedded specimens were subjected to sectioning. Deparaffinized sections were incubated with 3% hydrogen peroxidase solution for 10 min at room temperature to block endogenous peroxidase activity followed by incubation with citrate buffer (pH 6.0) for 10 min at 120°C to retrieve the antigen. After blocking with 3% BSA in PBS for 30 min at room temperature, the sections were incubated with primary antibodies at 4°C overnight and then with the secondary antibody (Envision^+^; Dako, Tokyo, Japan) at room temperature for 45 min followed by the addition of DAB. The sections were also stained with hematoxylin for 1 min. For the validation of the anti‐SNX9 antibody, 50 μl of crude biotinylated SNX9 recombinant proteins (WT, ΔLC, or LC‐PX) and anti‐SNX9 antibody (dilution 1:750) were pre‐incubated in 200 μl of 3% BSA in PBS buffer at 4°C overnight. The mixture including the pre‐absorbed antibody was used as the primary antibody for immunohistochemistry. Hematoxylin and eosin (H&E) staining of colorectal cancer tissues was carried out as described previously (Kiyoi, [2018](#jcp28346-bib-0026){ref-type="ref"}). The stained specimens were observed using the all‐in‐one fluorescence microscope BIOREVO BZ‐9000 (KEYENCE, Tokyo, Japan). The images were analyzed with the BZ‐II analyzer (KEYENCE) and Fiji (NIH). We defined epithelial and endothelial cells as SNX9‐positive when the signals for the SNX9‐DAB staining were positive above the threshold 90.

2.20. Human colorectal cancer samples {#jcp28346-sec-0220}
-------------------------------------

All human colorectal cancer samples were collected from the archives of the Department of Molecular Pathology, Ehime University Graduate School of Medicine and Division of Diagnostic Pathology, Ehime University Hospital. Clinical and pathological information was obtained from the pathology records at Ehime University Hospital. This study was approved by the Institutional Review Board of Ehime University Hospital (approved IRB protocol number: 1611003). Informed consent was obtained from all subjects. All experiments were performed by following the approved study plan and relevant guidelines.

2.21. Clinical database analysis {#jcp28346-sec-0230}
--------------------------------

The survival analysis was performed by the Kaplan--Meier method on the patients with clinical colorectal cancer. We subjected Gene Expression Omnibus (GEO) datasets (accession number, GSE14333 and GSE17536) to survival analysis which was executed by the 'ggplot2′, "survminer," and "survival" packages with R (ver. 3.4.1.). The GSE14333 (Jorissen et al., [2009](#jcp28346-bib-0022){ref-type="ref"}) and GSE17536 (Smith et al., [2010](#jcp28346-bib-0050){ref-type="ref"}) datasets contain the clinical status and expression data of SNX9 collected using the Affymetrix Human Genome U133 Plus 2.0 Array.

2.22. Statistical analyses {#jcp28346-sec-0240}
--------------------------

Statistical analyses was carried out by the Student\'s two‐tailed *t* test. The log‐rank test in survival analysis was performed by the "survminer" package in R (ver. 3.4.1.).

3. RESULTS {#jcp28346-sec-0250}
==========

3.1. A genetic screen to identify novel angiogenic factors using SNX siRNA library {#jcp28346-sec-0260}
----------------------------------------------------------------------------------

We reasoned that the regulators of membrane trafficking are essential for angiogenesis. Sorting nexins (SNXs) are critical factors for a variety of intracellular membrane trafficking and the human genome possesses 33 SNX genes (Table [1](#jcp28346-tbl-0001){ref-type="table"}; Cullen, [2008](#jcp28346-bib-0011){ref-type="ref"}). To examine if SNXs regulate angiogenesis, we performed the siRNA screening against 33 SNX genes (Figure [1](#jcp28346-fig-0001){ref-type="fig"}a,b). We found that SNX9 knockdown drastically inhibited the tube formations of HUVECs in an in vitro assay system that mimics in vivo angiogenesis (Arnaoutova & Kleinman, [2010](#jcp28346-bib-0002){ref-type="ref"}; Figure [1](#jcp28346-fig-0001){ref-type="fig"}a,b). The tube length of the SNX9‐knockdown cells was reduced approximately 75% compared to that of the control cells (Figure [1](#jcp28346-fig-0001){ref-type="fig"}b).

![SNX siRNA screening to identify novel angiogenic factors in HUVECs. (a) Confocal images of tube formation. HUVECs seeded on collagen I gel were treated with the control or SNXs siRNA (SNX1‐33) and packed on collagen I followed by VEGF stimulation for 66 hr. HUVECs were visualized by the staining of F‐actin with rhodamine‐labeled phalloidin. Bars, 200 µm. (b) The quantitation of (a). A total of 10 tubes were analyzed. Data shows are the mean ± *SEM*. The blue and red bars indicate the tube length of sicontrol‐ and siSNX9‐treated HUVECs, respectively. HUVEC: human umbilical vein endothelial cells; SEM: standard error of mean; siRNA: small interfering RNA; SNX: sorting nexin; VEGF: vascular endothelial growth factor \[Color figure can be viewed at wileyonlinelibrary.com\]](JCP-234-17280-g001){#jcp28346-fig-0001}

3.2. SNX9 is required for tube formation of human umbilical vein endothelial cells {#jcp28346-sec-0270}
----------------------------------------------------------------------------------

We next used multiple siRNA oligos to corroborate the involvement of SNX9 in tube formation in HUVECs. We transfected three different siRNA oligos targeting SNX9 and the knockdown efficiency was confirmed by western blot analysis (Figure [2](#jcp28346-fig-0002){ref-type="fig"}a). The tube formation was significantly suppressed by SNX9 knockdown using the three different siRNA oligos (Figure [2](#jcp28346-fig-0002){ref-type="fig"}b). The tube length of those SNX9‐depleted cells was reduced approximately 75% compared to that of the control HUVECs (Figure [2](#jcp28346-fig-0002){ref-type="fig"}b). Since we noticed that SNX9‐knockdown HUVECs did not extend well on collagen I gels during the tube formation assay compared to the control cells (Figure [2](#jcp28346-fig-0002){ref-type="fig"}b), we next examined the cell spreading activity on the Matrigel basement membrane (BM). One hour after seeding on the BD Matrigel™ BM, the control HUVEC spread and the size was approximately 1600 μm^2^ (Figure [2](#jcp28346-fig-0002){ref-type="fig"}c). In contrast, the cell shape of SNX9‐knockdown HUVECs was still round and its cell size was approximately 400--800 μm^2^ (Figure [2](#jcp28346-fig-0002){ref-type="fig"}c). HUVECs form networks on the Matrigel upon long‐time incubation, which also mimics in vivo angiogenesis (Ohnuki et al., [2012](#jcp28346-bib-0039){ref-type="ref"}). As shown in Figure [2](#jcp28346-fig-0002){ref-type="fig"}d, the control HUVECs formed networks upon incubation on the Matrigel for 12 hr. In contrast, by the knockdown of SNX9, the network formation by HUVECs on the Matrigel was drastically inhibited (Figure [2](#jcp28346-fig-0002){ref-type="fig"}d). The network length was reduced approximately 80% by the depletion of SNX9 (Figure [2](#jcp28346-fig-0002){ref-type="fig"}d). The expression of Myc‐tagged siRNA‐resistant SNX9 cDNA partially restored the inhibition of network formation in SNX9‐knockdown HUVECs, excluding the off‐target effect of siRNA (Figure [2](#jcp28346-fig-0002){ref-type="fig"}e,f). Together, these data suggested that SNX9 is essential for angiogenesis in HUVECs.

![SNX9 is essential for tube formation in HUVECs. (a) Western blot analysis of HUVEC lysates 72 hr posttransfection of siRNAs. (b) Confocal images and quantitation of tube formation. HUVECs seeded on collagen I gel were treated with control, or SNX9 siRNAs (siSNX9 \#1--\#3) and packed on collagen I followed by VEGF stimulation for 66 hr. HUVECs were visualized by the staining for F‐actin with rhodamine‐labeled phalloidin. Bars, 200 µm. A total of 30 of the tubes from three independent experiments were analyzed. Data shows the mean ± *SEM*. \*\*\**p* \< .001. (c) Confocal images and quantitation of cell spreading. HUVECs were seeded on the Matrigel followed by incubation for 1 hr. The cells were visualized by staining of F‐actin with rhodamine‐labeled phalloidin. Bars, 20 µm. The size of 50 cells from three independent experiments were analyzed. Data shown are the mean ± SEM. \*\*\**p* \< .001. (d) Confocal images and quantitation of network formation. HUVECs were seeded on the Matrigel followed by incubation for 12 hr. The cells were visualized by staining for F‐actin with rhodamine‐labeled phalloidin. Bars, 200 µm. A total of 30 of networks from three independent experiments were analyzed. Data shown are the mean ± *SEM*. \*\*\**p* \< .001. (e,f) Rescue experiments for SNX9 knockdown: (e) Western blot analysis of cell lysates of HUVECs infected with siRNA resistant‐Myc‐SNX9‐carrying lentivirus. (f) Confocal images and quantitation of network formation of HUVECs infected with siRNA resistant‐Myc‐SNX9‐carrying lentivirus (f). HUVECs were seeded on the Matrigel followed by incubation for 12 hr. Cells were visualized by the staining for F‐actin with rhodamine‐labeled phalloidin. The Myc‐SNX9 was labeled with anti‐Myc antibody. Bars, 200 µm. Magnifications of the squared areas are shown in the lower panels (bars, 20 µm). A total of 30 of the tubes from three independent experiments were analyzed. Data shown are the mean ± SEM. \*\*\**p* \< .001. HUVEC: human umbilical vein endothelial cells; SEM: standard error of mean; siRNA: small interfering RNA; SNX9: sorting nexin 9; VEGF: vascular endothelial growth factor \[Color figure can be viewed at wileyonlinelibrary.com\]](JCP-234-17280-g002){#jcp28346-fig-0002}

3.3. SNX9 regulates recycling of integrin β1 from endosomes to the plasma membrane {#jcp28346-sec-0280}
----------------------------------------------------------------------------------

We next sought to elucidate the mechanism by which SNX9 regulates tube formation in HUVECs. Integrin β1, an adhesion molecule, is essential for angiogenesis and the reduction in the levels of integrin β1 on the cell surface inhibits the cell spreading on the Matrigel (Hongu et al., [2015](#jcp28346-bib-0017){ref-type="ref"}; Maekawa et al., [2017](#jcp28346-bib-0031){ref-type="ref"}). Since we noticed that the cell spreading on the Matrigel in SNX9‐knockdown HUVECs was drastically impaired (Figure [2](#jcp28346-fig-0002){ref-type="fig"}c,d), we reasoned that the surface integrin β1 would decrease by the depletion of SNX9. As expected, by staining HUVECs without membrane permeabilization, we found that the fluorescence intensity of integrin β1 on cell surface was significantly decreased by the SNX9 knockdown (Figure [3](#jcp28346-fig-0003){ref-type="fig"}a). The decrease in the surface levels of integrin β1 by the SNX9 knockdown was also confirmed by biotinylation of the surface proteins (Figure [3](#jcp28346-fig-0003){ref-type="fig"}b). Both experiments showed that the cell surface integrin β1 levels were decreased to approximately 40--60% by the SNX9 knockdown. The population of surface integrin β1 is controlled by endocytosis from the PM to endosomes and the recycling from endosomes to the PM (De Franceschi, Hamidi, Alanko, Sahgal, & Ivaska, [2015](#jcp28346-bib-0014){ref-type="ref"}). Since total protein expression of integrin β1 was not affected in the SNX9‐knockdown HUVECs (Figure [3](#jcp28346-fig-0003){ref-type="fig"}c), integrin β1 would be relocalized from the PM to intracellular compartments by the SNX9 depletion. As expected, integrin β1 was localized in intracellular punctate structures by the SNX9 knockdown, whereas, integrin β1 localized in the PM in the control HUVECs (Figure [3](#jcp28346-fig-0003){ref-type="fig"}d). We then determined the integrin β1‐positive intracellular compartments in the cells depleted of SNX9. The co‐localization analysis with several endocytic proteins (Rab5, early endosomes; Rab11, recycling endosomes; Rab7, late endosomes; LAMP1, lysosomes) indicated that integrin β1 localized mostly to early endosomes/recycling endosomes in the SNX9‐knockdown cells (Figure [3](#jcp28346-fig-0003){ref-type="fig"}e). These data suggested that SNX9 functioned in not the degradation pathway but the recycling pathway of integrin β1.

![SNX9 regulates localization of cell surface integrin β1 and the recycling pathway of the cargo in HUVECs. (a) Confocal images and the quantitation of HUVECs fixed after 72 hr transfection of siRNA and stained for integrin β1 by Alexa488‐conjugated TS2/16, without membrane permeabilization. Bars, 20 µm. Fifty cells from three independent experiments were analyzed. Data shown are the mean ± *SEM*. \*\*\**p* \< .001; \**p* \< .05. (b) Surface proteins were biotinylated, collected with streptavidin beads, and the total and cell surface integrin β1 were detected by TS2/16. The numbers indicate the band intensity of surface/total integrin β1 (normalized to siControl). (c) Western blots of HUVEC lysates 72 hr posttransfection of siRNAs. The numbers indicate the band intensity of total integrin β1/GAPDH (normalized to siControl). (d) Confocal images of HUVECs fixed after 72 hr transfection of siRNA, permeabilized, and stained for integrin β1 by P5D2. Bars, 20 µm. Inset: magnifications of the squared areas. (e) Confocal images of SNX9 knockdown HUVECs expressing the GFP‐tagged organelle markers: Rab5 (early endosomes), Rab11 (recycling endosomes), Rab7 (late endosomes), and LAMP1 (lysosomes) by lentiviral infection. Bars, 20 µm. (f) Internalization of integrin β1. HUVECs were treated with control siRNA and SNX9 siRNA \#1 for 72 hr. Surface integrin β1 was labeled with Alexa488‐TS2/16 and chased in medium for 10 min. The fluorescence intensity of Alexa488‐TS2/16 is shown as a percentage of that at 0 min (the fluorescence intensity on the cell surface before quenching). Fifty cells from three independent experiments were analyzed. Data shown are the mean ± *SEM*. n. s., not significant. (g) Recycling of integrin β1. HUVECs were treated with the control siRNA and SNX9 siRNA \#1 for 72 hr. The fluorescence intensity of Alexa488‐TS2/16 is shown as a percentage of that at 0 min. Fifty cells from three independent experiments were analyzed. Data shown are the mean ± SEM. \*\*, *p* \< .01; \*, *p* \< .05. (h) Internalization of transferrin. The HUVECs were treated with the control siRNA and SNX9 siRNA \#1 for 72 hr. The cells were incubated with Alexa488‐Tfn for 5 min, acid‐washed, and fixed. The fluorescence intensity of Alexa488‐Tfn is shown. Fifty cells from three independent experiments were analyzed. Data shown are the mean ± *SEM*. n. s., not significant. (i) Recycling of transferrin. The HUVECs were treated with control siRNA and SNX9 siRNA \#1 for 72 hr. The fluorescence intensity of Alexa488‐Tfn is shown as the percentage of that at 0 min. Fifty cells from three independent experiments were analyzed. Data shown are the mean ± *SEM*. \*\**p* \< .01; \**p* \< .05. GAPDH: glyceraldehyde 3‐phosphate dehydrogenase; HUVEC: human umbilical vein endothelial cells; SEM: standard error of mean; siRNA: small interfering RNA; SNX9: sorting nexin 9 \[Color figure can be viewed at wileyonlinelibrary.com\]](JCP-234-17280-g003){#jcp28346-fig-0003}

We then compared the trafficking of integrin β1 in control and SNX9‐depleted HUVECs. First, the internalization of integrin β1 from the PM was measured. As shown in Figure [3](#jcp28346-fig-0003){ref-type="fig"}f, the intensity of Alexa488‐integrin β1 after the 10‐min chase was about 50% compared to the fluorescence intensity on cell surface before chase in both the control and SNX9‐knockdown cells. SNX9 knockdown did not affect the VEGF‐induced internalization of integrin β1 (Figure S1). These data indicated that SNX9 is not involved in the internalization of integrin β1 from the PM. Secondly, the recycling of integrin β1 from early endosomes/recycling endosomes to the PM was measured. As shown (Figure [3](#jcp28346-fig-0003){ref-type="fig"}g), approximately 40% of integrin β1 in the endosomes at time = 0 was recycled back to the PM in the control cells after the 60‐min chase. In contrast, only approximately 20% of integrin β1 in the endosomes at time = 0 was recycled back to the PM after the 60‐min chase in the cells depleted of SNX9. These results suggested that the SNX9 knockdown significantly delayed the recycling of integrin β1 from the endosomes to the PM. We also examined the trafficking of transferrin, which follows the same endocytic recycling pathway as integrin β1. We confirmed no difference between the control and SNX9‐knockdown cells in the internalization of transferrin (Figure [3](#jcp28346-fig-0003){ref-type="fig"}h). In contrast, the recycling of transferrin, like that of integrin β1, was delayed by the SNX9 knockdown (Figure [3](#jcp28346-fig-0003){ref-type="fig"}i). Together, SNX9 regulated the recycling of integrin β1 from early endosomes/recycling endosomes to the PM in HUVECs, and the defect of recycling of integrin β1 may account for the decrease in the level of integrin β1 on the cell surface of SNX9‐knockdown cells.

Integrin β1 on the cell surface is critical for cell migration and cell proliferation (Seguin, Desgrosellier, Weis, & Cheresh, [2015](#jcp28346-bib-0045){ref-type="ref"}). SNX9 knockdown significantly inhibited the migration of HUVEC on collagen I‐coated dishes (Figure S2a). Depletion of SNX9 drastically decreased cell proliferation of HUVEC in a VEGF‐independent manner (Figure S2b). These data suggested that SNX9 regulates fundamental endothelial functions in HUVEC

3.4. SNX9 expression profiles in tumor endothelial cells in human colorectal cancer tissues {#jcp28346-sec-0290}
-------------------------------------------------------------------------------------------

Finally, we sought to clinically validate the functions of SNX9 in endothelial cells. It is well known that the activity of tumor angiogenesis in colorectal cancer is extremely high compared to various other cancers (Mathonnet et al., [2014](#jcp28346-bib-0034){ref-type="ref"}). Since SNX9 positively regulates tube formation that mimics in vivo angiogenesis in HUVECs, we hypothesized that the expression of SNX9 protein is high in tumor endothelial cells in the human colorectal cancer tissues. We first confirmed that the anti‐SNX9 antibody was suitable for immunohistochemistry of the human colorectal cancer tissues, by the absorption experiments. By pre‐incubation of the anti‐SNX9 antibody with biotinylated recombinant full‐length SNX9 or the LC‐PX domain of SNX9, in which the antigen for the anti‐SNX9 antibody is included, the staining for SNX9 was diminished (Figure [4](#jcp28346-fig-0004){ref-type="fig"}a,b). In contrast, by preincubation of the anti‐SNX9 antibody with biotinylated recombinant LC domain‐deleted SNX9 (ΔLC), in which the amino acid sequence targeted by the anti‐SNX9 antibody is excluded, the staining for SNX9 was detected (Figure [4](#jcp28346-fig-0004){ref-type="fig"}a,b). These data suggested that the anti‐SNX9 antibody recognized the SNX9 protein in the human colorectal cancer tissues.

![Expression of SNX9 in human colorectal cancer tissues. (a) The domain structure of SNX9 and western blot analysis of recombinant biotinylated (Bio‐) SNX9 proteins. The numbers in the domain structure represent the order of amino acids from the N‐terminus. The red line indicates the location of antigen for the anti‐SNX9 antibody used in this study. The anti‐SNX9 antibody failed to recognize Bio‐SNX9 (ΔLC) recombinant proteins because the antigen amino acid sequence is located in the LC domain. (b) Validation of the anti‐SNX9 antibody for immunohistochemistry in the human colorectal cancer tissues. The anti‐SNX9 antibody was preincubated with biotinylated full‐length SNX9 (Bio‐SNX9 \[FL\]), LC domain‐deleted SNX9 (Bio‐SNX9 \[ΔLC\]), or LC‐PX domain of SNX9 (Bio‐LC‐PX). The mixtures of the antibody and recombinant proteins were used as primary antibody. The neighboring sections of a human colorectal cancer tissue were subjected to H&E staining and immunohistological staining for SNX9. Bars, 500 µm. Inset: magnifications of the yellow squared areas. (c) Representative images of the H&E staining and immunohistological staining for SNX9 and CD31. The neighboring sections of the human normal colon and colorectal cancer tissues were subjected to H&E staining and immunohistochemistry. In normal colon, CD31^+^‐endothelial cells are SNX9‐negative (yellow arrows). In colorectal cancer tissues, CD31^+^‐endothelial cells are SNX9‐positive (yellow arrowheads). Bars, 500 µm (HE staining, left panels of SNX9 and CD31 staining) and 50 µm (right panels of SNX9 and CD31 staining). Magnifications of the squared areas are shown on the right. H & E: hematoxlyin--eosin; SNX9: sorting nexin 9 \[Color figure can be viewed at wileyonlinelibrary.com\]](JCP-234-17280-g004){#jcp28346-fig-0004}

We then examined the protein expression of SNX9 in tumor endothelial cells in human colorectal cancer tissues. A total of 57 individual tumor tissues from patients with colorectal cancer were subjected to immunohistochemistry. As shown in Figure [4](#jcp28346-fig-0004){ref-type="fig"}c, less staining for SNX9 was observed in CD31^+^‐endothelial cells (yellow arrows) in the normal colorectal tissues. In contrast, the high‐level expression of SNX9 protein was detected in CD31^+^‐tumor endothelial cells (Figure [4](#jcp28346-fig-0004){ref-type="fig"}c; yellow arrowheads) in the human colorectal cancer tissues (Figure [4](#jcp28346-fig-0004){ref-type="fig"}c). The protein expression of SNX9 in tumor endothelial cells was detected regardless of stage, histological grade, the location of the tumor, and level of invasion in individual colorectal cancer tissues from 57 human patients (Table [2](#jcp28346-tbl-0002){ref-type="table"}). The expression of SNX9 protein was detected in tumor endothelial cells in the colorectal cancer tissues through stages I, II, III, and IV (Table [2](#jcp28346-tbl-0002){ref-type="table"}). More than 75% of colorectal cancer tissues (stages II, III, and IV) exhibited staining for SNX9 in tumor endothelial cells. SNX9 was expressed in tumor endothelial cells of well, moderately, and poorly differentiated colorectal cancer tissues (Table [2](#jcp28346-tbl-0002){ref-type="table"}). In this study, we collected only one mucinous type colorectal cancer tissue, in which the SNX9 expression in tumor endothelial cells was negative. We also classified the colorectal cancer tissues by the location of tumors. SNX9 was expressed in tumor endothelial cells in more than 65% of colorectal cancer tissues regardless of their location in the colon, except for the appendix vermiformis. In this study, we collected only one colorectal cancer tissue from appendix vermiformis, in which the SNX9 expression in tumor endothelial cells was negative. Approximately 80% of colorectal cancer tissues with lymphovascular invasion highly expressed the SNX9 protein in tumor endothelial cells (Table [2](#jcp28346-tbl-0002){ref-type="table"}). In regard to the level of invasion, the high‐level expression of the SNX9 protein was detected in tumor endothelial cells of more than 65% of T2, T3, and T4 colorectal cancer tissues (Table [2](#jcp28346-tbl-0002){ref-type="table"}). In this study, we collected only one T1 colorectal cancer tissue, in which the SNX9 expression in tumor endothelial cells was negative. These data suggested that the high‐level expression of SNX9 in tumor endothelial cells might enhance tumor angiogenesis in colorectal tumors, and contribute to the development of colorectal tumors.

###### 

Expression profile of SNX9 protein in human colorectal cancer tissues. Total 57 of human colorectal cancer tissues were subjected to immunohistochemistry for SNX9. The number of human colorectal cancer tissues with SNX9‐positive tumor endothelial or epithelial cells were counted. See also Materials and Methods

                                           Number and percentage of human colorectal cancer tissues   
  ---------------------------------------- ---------------------------------------------------------- --------------
  Stage                                                                                               
  I                                        1/3 (33%)                                                  2/3 (67%)
  II                                       17/20 (85%)                                                17/20 (85%)
  III                                      22/29 (76%)                                                25/29 (86%)
  IV                                       4/4 (100%)                                                 4/4 (100 %)
  Histological grade                                                                                  
  Well differentiated                      19/22 (86 %)                                               19/22 (86 %)
  Moderately differentiated                23/30 (77 %)                                               25/30 (83 %)
  Poorly differentiated (solid type)       2/3 (67 %)                                                 3/3 (100 %)
  Poorly differentiated (non‐solid type)   1/1 (100 %)                                                1/1 (100 %)
  Mucinous                                 0/1 (0 %)                                                  1/1 (100 %)
  Location of tumor                                                                                   
  Appendix vermiformis                     0/1 (0 %)                                                  1/1 (100 %)
  Cecum                                    2/3 (67 %)                                                 3/3 (100 %)
  Ascending colon                          11/13 (85 %)                                               12/13 (92 %)
  Transverse colon                         5/5 (100 %)                                                5/5 (100 %)
  Descending colon                         3/5 (60 %)                                                 4/5 (80 %)
  Sigmoid colon                            9/11 (82 %)                                                9/11 (82 %)
  Rectum                                   15/19 (79 %)                                               15/19 (79 %)
  Lymphovascular invasion                                                                             
  Present                                  45/56 (80 %)                                               49/56 (88 %)
  Absent                                   0/1 (0 %)                                                  0/1 (0 %)
  Level of invasion                                                                                   
  T1                                       0/1 (0 %)                                                  0/1 (0 %)
  T2                                       2/3 (67 %)                                                 3/3 (100 %)
  T3                                       27/34 (79 %)                                               29/34 (85 %)
  T4                                       16/19 (84 %)                                               17/19 (89 %)

*Note*. SNX9: sorting nexin 9.
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3.5. High expression of SNX9 mRNA significantly correlated with poor prognosis of human colorectal cancer {#jcp28346-sec-0300}
---------------------------------------------------------------------------------------------------------

We noticed that protein expression of SNX9 was high not only in tumor endothelial cells but also in epithelial cells of human colorectal cancer tissues (Figure [4](#jcp28346-fig-0004){ref-type="fig"}c). Its expression profile was similar to that in tumor endothelial cells (Table [2](#jcp28346-tbl-0002){ref-type="table"}). These data suggested that SNX9 may also have critical roles in colorectal cancer epithelial cells, and SNX9 expression could determine the prognosis of human colorectal cancers. We thus examined if the expression level of SNX9 correlates with the prognosis of human colorectal cancers using the GEO datasets (accession numbers GSE14333 and GSE17536; Jorissen et al., [2009](#jcp28346-bib-0022){ref-type="ref"}; Smith et al., [2010](#jcp28346-bib-0050){ref-type="ref"}). We found that the high mRNA expression of SNX9 significantly correlated with poor prognosis for both the overall survival and disease‐free survival of patients with colorectal cancers (Figure [5](#jcp28346-fig-0005){ref-type="fig"}; *p* = .003; high: *n* = 99, low: *n* = 78; *p* \< .0001, high: *n* = 25, low: *n* = 201, respectively). These data suggested that SNX9 functions as an oncogenic gene in the development of human colorectal cancers.

![Survival analysis with SNX9 expression profiles in human colorectal cancers. The Kaplan--Meier plot with SNX9 expression profiles in GSE17536 and GSE14333 datasets using endpoint overall survival status (left) and endpoint disease‐free survival status (right). Shading along the curve showed 95% confidential interval. In human colorectal cancers, the high expression of SNX9 was correlated to poor prognosis for overall survival (high: *n* = 99; low: *n* = 78) and disease‐free survival (high: *n* = 25; low: *n* = 201). SNX9: sorting nexin 9 \[Color figure can be viewed at wileyonlinelibrary.com\]](JCP-234-17280-g005){#jcp28346-fig-0005}

4. DISCUSSION {#jcp28346-sec-0310}
=============

SNX9 is a multifunctional protein which regulates endocytosis (e.g., clathrin‐mediated endocytosis, clathrin‐independent endocytosis, macropinocytosis), cell migration, cell invasion, and cell division (Bendris & Schmid, [2017](#jcp28346-bib-0004){ref-type="ref"}). In the present study, we found that SNX9 regulates the recycling of cargos (integrin β1, transferrin) from early/recycling endosomes to the plasma membrane in HUVECs (Figure [2](#jcp28346-fig-0002){ref-type="fig"}e--i). In the process of clathrin‐mediated endocytosis, SNX9 is recruited to clathrin‐coated pits by the recognition of membrane curvature and phosphoinositides (Daste et al., [2017](#jcp28346-bib-0012){ref-type="ref"}; Schoneberg et al., [2017](#jcp28346-bib-0044){ref-type="ref"}). SNX9 in the clathrin‐coated pits facilitates the recruitment and/or activation of dynamin, which catalyzes membrane fission from the plasma membrane (Schoneberg et al., [2017](#jcp28346-bib-0044){ref-type="ref"}). In the process of recycling of cargos such as integrin β1 and transferrin from early/recycling endosomes, SNX9 may also function in the membrane scission from early or/and recycling endosomes in HUVECs.

Recently, SNX9 has been shown to regulate invadopodia formation and cell invasion in breast cancer cells (Bendris, Stearns, et al., [2016](#jcp28346-bib-0005){ref-type="ref"}; Bendris, William, et al., [2016](#jcp28346-bib-0006){ref-type="ref"}). SNX9 enhances the internalization of membrane‐type‐1 matrix metalloproteinase (MT1‐MMP) from the plasma membrane, which negatively regulates the invadopodia formation (Bendris, Stearns, et al., [2016](#jcp28346-bib-0005){ref-type="ref"}). Loss of SNX9 increased the surface level of a disintegrin and metalloproteases 9 (ADAM9) owing to the inhibition of endocytosis of ADMA9, resulting in the increase in shedding of Ephrin receptor B4 at the plasma membrane (Mygind et al., [2018](#jcp28346-bib-0037){ref-type="ref"}). SNX9 is also required for cell migration through the inhibition of the RhoA‐Rho‐associated protein kinase pathway (Bendris, Williams, et al., [2016](#jcp28346-bib-0006){ref-type="ref"}). Pathologically, its protein expression is lowered in primary breast cancer tumors and upregulated in metastatic breast cancer tumors (Bendris, Stearns, et al., [2016](#jcp28346-bib-0005){ref-type="ref"}; Bendris, Williams, et al., [2016](#jcp28346-bib-0006){ref-type="ref"}). In contrast to the protein expression profile of SNX9 in human breast cancer tissues, we found that the SNX9 protein was expressed in both epithelial and endothelial cells of human colorectal cancer tissues regardless of their pathological characteristics (Table [2](#jcp28346-tbl-0002){ref-type="table"}). SNX9 may also function in cell invasion/migration in the epithelial cells of colorectal cancers, in addition to its novel function in angiogenesis of the endothelial cells revealed in this study. Clinically, the recent meta‐analysis with more than 1.4 million patients with colorectal cancer showed that the risk of patient death with left‐sided primary colon tumor was 20% lower than patients with right‐sided primary colon tumor (Petrelli et al., [2016](#jcp28346-bib-0041){ref-type="ref"}). The SNX9 expression in both the epithelial and endothelial cells in the colorectal cancer tissues was positive regardless of the tumor location (Table [2](#jcp28346-tbl-0002){ref-type="table"}), suggesting that SNX9 is not likely to be involved in the determination of prognostic differences between the left‐sided and right‐sided colorectal tumors. The upregulation of SNX9 protein in breast and colorectal cancer tissues could be due to the inhibition of its protein degradation and/or enhancement of its transcription. The E3 ubiquitin ligase Itch has a potential to ubiquitinate SNX9, leading to its degradation in the HEK293 cells (Baumann, Lindholm, Rimoldi, & Levy, [2010](#jcp28346-bib-0003){ref-type="ref"}). The transcription factor STAT5B is required for the transcription of SNX9 mRNA in human CD4^+^T cells (Kanai et al., [2014](#jcp28346-bib-0023){ref-type="ref"}). The regulatory mechanisms for SNX9 protein expression in endothelial cells and cancer cells would be investigated in the future.

Our siRNA screening against 33 SNX genes showed that knockdown of sorting nexin 5 (SNX5) also inhibited tube formation of HUVEC (Figure [1](#jcp28346-fig-0001){ref-type="fig"}). SNX5 knockdown affected neither protein expression, cellular localization nor the surface level of integrin β1 (Figure S3). How SNX5 is involved in tube formation is unknown. Other members of sorting nexin family, sorting nexin 1 (SNX1) and sorting nexin 10 (SNX10) have been shown to act as tumor suppressors of colorectal cancers (Bian et al., [2016](#jcp28346-bib-0008){ref-type="ref"}; Huang et al., [2011](#jcp28346-bib-0019){ref-type="ref"}; Le et al., [2018](#jcp28346-bib-0028){ref-type="ref"}; Nguyen et al., [2006](#jcp28346-bib-0038){ref-type="ref"}; Zhang et al., [2018](#jcp28346-bib-0052){ref-type="ref"}). Both mRNA and protein levels of SNX1 were significantly decreased in human colorectal cancer tissues (Nguyen et al., [2006](#jcp28346-bib-0038){ref-type="ref"}). SNX1 knockdown showed increased proliferation and decreased apoptosis in colorectal cancer cells (Nguyen et al., [2006](#jcp28346-bib-0038){ref-type="ref"}). SNX10 expression was also decreased in human colorectal cancer tissues (Zhang et al., [2018](#jcp28346-bib-0052){ref-type="ref"}). Depletion of SNX10 promoted mouse colorectal tumor formation and cell proliferation/survival in human colorectal cancer cells owing to increased mammalian target of rapamycin activation through chaperone‐mediated autophagy (Le et al., [2018](#jcp28346-bib-0028){ref-type="ref"}; Zhang et al., [2018](#jcp28346-bib-0052){ref-type="ref"}). In contrast to SNX1 and SNX10 as antioncogenic genes, our present study suggested that SNX9 is an oncogenic gene of colorectal cancers. SNX1 positively regulates endocytosis of epidermal growth factor receptor (EGFR) and overexpression of SNX1 reduced the cell surface levels of EGFR (Kurten, Cadena, & Gill, [1996](#jcp28346-bib-0027){ref-type="ref"}). Here, we showed that SNX9 is essential for the recycling of integrin β1 and that knockdown of SNX9 reduced the cell surface levels of integrin β1. The distinct site of action of individual SNXs, i.e., endocytosis from the PM or recycling traffic from endosomes, may dictate their different roles in tumorigenesis.

Integrins are receptors on the plasma membrane for cell adhesion to the extracellular matrices such as fibronectin and collagen (Hynes, [2002](#jcp28346-bib-0020){ref-type="ref"}). The α and β subunits of integrins noncovalently form heterodimers (Paul, Jacquemet, & Caswell, [2015](#jcp28346-bib-0040){ref-type="ref"}). Accumulated evidence have shown that angiogenesis requires proper cellular adhesion of endothelial cells to the extracellular matrix, which is mediated by the cell surface integrins (Carmeliet & Jain, [2011](#jcp28346-bib-0009){ref-type="ref"}). Inhibitory antibodies and peptides for integrin α1/β1, α2/β1, and α5/β1 suppressed angiogenesis (Kim, Bell, Mousa, & Varner, [2000](#jcp28346-bib-0025){ref-type="ref"}; Senger et al., [1997](#jcp28346-bib-0046){ref-type="ref"}). Pathologically, the inhibitory antibodies for integrin α1/β1 and α2/β1 also reduced the tumor angiogenesis and tumor growth of human squamous cell carcinoma xenografts (Senger et al., [2002](#jcp28346-bib-0047){ref-type="ref"}). The combination of 5‐fluorouracil infusion and the inhibition of integrin α5/β1 by a small peptide (ATN‐161) reduced the colorectal liver metastasis (Stoeltzing et al., [2003](#jcp28346-bib-0051){ref-type="ref"}). Although the concept that the inhibition of integrin β1 leads to the suppression of angiogenesis has been proved both in vitro and in vivo, to date, inhibitory antibodies and antagonizing peptides targeting the cell surface integrin β1 have not been successfully developed as antiangiogenic drugs for the cancer therapy. In the present study, we identified SNX9 as a novel angiogenic factor that regulates the recycling pathway of integrin β1. Other molecules that regulate integrin β1 recycling such as Arf6 and CUL3/ANKFY1 complex are also essential for angiogenesis (Hongu et al., [2015](#jcp28346-bib-0017){ref-type="ref"}; Maekawa et al., [2017](#jcp28346-bib-0031){ref-type="ref"}). The machinery of integrin β1 trafficking could also be targets for the development of novel antiangiogenic drugs.
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